相似文献
1
Grand challenge commentary: Informative diagnostics for personalized medicine.
Nat Chem Biol. 2010 Dec;6(12):857-9. doi: 10.1038/nchembio.488.
2
Companion diagnostics: the next step in personalized clinical care.
Genet Test Mol Biomarkers. 2012 Oct;16(10):1155-6. doi: 10.1089/gtmb.2012.1539.
3
Toward multiomics-based next-generation diagnostics for precision medicine.
Per Med. 2019 Mar;16(2):157-170. doi: 10.2217/pme-2018-0085. Epub 2019 Feb 28.
4
Role of Proteomics in the Development of Personalized Medicine.
Adv Protein Chem Struct Biol. 2016;102:41-52. doi: 10.1016/bs.apcsb.2015.09.002. Epub 2015 Nov 11.
5
Precision medicine: what's all the fuss about?
Scand J Clin Lab Invest Suppl. 2016;245:S2-5. doi: 10.1080/00365513.2016.1206434. Epub 2016 Aug 17.
6
Protein shakes - the future is not here yet for proteomic - based companion diagnostics, but it's coming.
Mol Oncol. 2011 Jun;5(3):220-3. doi: 10.1016/j.molonc.2011.04.003.
7
Implementing personalized cancer genomics in clinical trials.
Nat Rev Drug Discov. 2013 May;12(5):358-69. doi: 10.1038/nrd3979.
8
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.
J Intern Med. 2012 Feb;271(2):111-21. doi: 10.1111/j.1365-2796.2011.02498.x.
9
Biomarkers for precision medicine in airways disease.
Ann N Y Acad Sci. 2015 Jun;1346(1):18-32. doi: 10.1111/nyas.12809.
10
Genetics and genomics: the scientific drivers of personalized medicine.
Annu Rev Nurs Res. 2011;29:27-54. doi: 10.1891/0739-6686.29.27.
引用本文的文献
1
On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions.
Nat Med. 2012 Sep;18(9):1434-40. doi: 10.1038/nm.2913.
2
Resources and costs for microbial sequence analysis evaluated using virtual machines and cloud computing.
PLoS One. 2011;6(10):e26624. doi: 10.1371/journal.pone.0026624. Epub 2011 Oct 19.
本文引用的文献
1
Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound.
Cancer Res. 2010 Sep 15;70(18):7232-41. doi: 10.1158/0008-5472.CAN-10-0766. Epub 2010 Sep 7.
2
Applications of aptamers as sensors.
Annu Rev Anal Chem (Palo Alto Calif). 2009;2:241-64. doi: 10.1146/annurev.anchem.1.031207.112851.
3
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Oncogene. 2010 Jul 29;29(30):4245-52. doi: 10.1038/onc.2010.188. Epub 2010 May 24.
4
The application of mass-spectrometry-based protein biomarker discovery to theragnostics.
Br J Clin Pharmacol. 2010 Apr;69(4):367-78. doi: 10.1111/j.1365-2125.2009.03610.x.
5
Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
J Med Chem. 2010 Jun 24;53(12):4561-84. doi: 10.1021/jm100012m.
6
Cancer research. Melanoma drug vindicates targeted approach.
Science. 2009 Dec 18;326(5960):1619. doi: 10.1126/science.326.5960.1619.
7
Iterative in situ click chemistry creates antibody-like protein-capture agents.
Angew Chem Int Ed Engl. 2009;48(27):4944-8. doi: 10.1002/anie.200900488.
8
Screening and prostate-cancer mortality in a randomized European study.
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
9
Imaging in the era of molecular oncology.
Nature. 2008 Apr 3;452(7187):580-9. doi: 10.1038/nature06917.
10
The cancer biomarker problem.
Nature. 2008 Apr 3;452(7187):548-52. doi: 10.1038/nature06913.
Zotero 插件